|
|||||
|
|
Platelet MAO and amitriptyline treatment |
|
| Authors: | Earl Giller Peter Jatlow Donald Bialos Laurie Harkness John P. Docherty |
| Affiliation: | 1. Earl Giller, Jr., M.D., Ph.D., is Psychiatry Research Coordinator, Veterans Administration Medical Center, West Haven, CT, USA;2. Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT, USA;3. Peter Jatlow, M.D., is Professor of Laboratory Medicine and Psychiatry, Yale Psychiatric Institute, USA;4. Donald Bialos, M.D., is Research Psychiatrist, VA Medical Center, and Clinical Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT, USA;5. Laurie Harkness, M.S.W., is Associate in Research, VA Medical Center, and Clinical Instructor in Psychiatry, Yale University School of Medicine, New Haven, CT, USA;6. John P. Docherty, M.D., is Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT, USA |
| Abstract: | Some tricyclic antidepressants have been reported to inhibit monoamine oxidase (MAO) activity in vitro in addition to blocking the reuptake of norepinephrine and/or serotonin. While the inhibition of MAO is reversible, platelet MAO activity in depressed patients responding to amitriptyline treatment has been reported to be reduced after drug treatment. In a reverse design, we measured platelet MAO activity and drug levels in patients chronically being treated with amitriptyline and again 2 and 4 weeks after stopping the medication. Although tricyclic drug concentrations were initially within the therapeutic range and undetectable on placebo treatment, platelet MAO activities were unchanged. |
| Keywords: | Platelet monoamine oxidase amitriptyline depression |
| 本文献已被 ScienceDirect 等数据库收录！ | |